STAT’s Matthew Herper struck an industry nerve when he wrote that the drug development industry is “not prepared for the next wave of biotech innovation.”
His report ends on a somewhat dismal note: the industry is long on diagnosis (clinical development is too expensive) and short on cures.
Create a display name to comment
This name will appear with your comment
